220 related articles for article (PubMed ID: 27465068)
21. Release of soluble tryptase but only minor amounts of chymase activity from cutaneous mast cells.
Kivinen PK; Kaminska R; Naukkarinen A; Harvima RJ; Horsmanheimo M; Harvima IT
Exp Dermatol; 2001 Aug; 10(4):246-55. PubMed ID: 11493313
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall.
Takatu CM; Heringer APR; Aoki V; Valente NYS; de Faria Sanchez PC; de Carvalho JF; Criado PR
Immunol Res; 2017 Feb; 65(1):395-401. PubMed ID: 27530606
[TBL] [Abstract][Full Text] [Related]
23. Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue.
Hermes B; Feldmann-Böddeker I; Welker P; Algermissen B; Steckelings MU; Grabbe J; Henz BM
J Invest Dermatol; 2000 Jan; 114(1):51-5. PubMed ID: 10620115
[TBL] [Abstract][Full Text] [Related]
24. Mast Cells Are a Marked Source for Complement C3 Products That Associate with Increased CD11b-Positive Cells in Keratinocyte Skin Carcinomas.
Rahkola D; Laitala J; Siiskonen H; Pelkonen J; Harvima IT
Cancer Invest; 2019; 37(2):73-84. PubMed ID: 30689427
[TBL] [Abstract][Full Text] [Related]
25. Involvement of premacular mast cells in the pathogenesis of macular diseases.
Sato T; Morishita S; Horie T; Fukumoto M; Kida T; Oku H; Nakamura K; Takai S; Jin D; Ikeda T
PLoS One; 2019; 14(2):e0211438. PubMed ID: 30794552
[TBL] [Abstract][Full Text] [Related]
26. Thymosin beta 4 expression in normal skin, colon mucosa and in tumor infiltrating mast cells.
Nemolato S; Cabras T; Fanari MU; Cau F; Fraschini M; Manconi B; Messana I; Castagnola M; Faa G
Eur J Histochem; 2010 Feb; 54(1):e3. PubMed ID: 20353910
[TBL] [Abstract][Full Text] [Related]
27. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
Dyduch G; Okoń K; Pescarini E
Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
[TBL] [Abstract][Full Text] [Related]
28. Quantitative enzyme-histochemical analysis of tryptase- and chymase-containing mast cells in psoriatic skin.
Harvima IT; Naukkarinen A; Harvima RJ; Aalto ML; Neittaanmäki H; Horsmanheimo M
Arch Dermatol Res; 1990; 282(7):428-33. PubMed ID: 1706585
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions.
Kankkunen JP; Harvima IT; Naukkarinen A
Int J Cancer; 1997 Jul; 72(3):385-8. PubMed ID: 9247277
[TBL] [Abstract][Full Text] [Related]
30. Role of mast cell chymase and tryptase in the progression of atherosclerosis: study in 44 autopsied cases.
Ramalho LS; Oliveira LF; Cavellani CL; Ferraz ML; de Oliveira FA; Miranda Corrêa RR; de Paula Antunes Teixeira V; De Lima Pereira SA
Ann Diagn Pathol; 2013 Feb; 17(1):28-31. PubMed ID: 22658852
[TBL] [Abstract][Full Text] [Related]
31. Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses.
Ramu S; Akbarshahi H; Mogren S; Berlin F; Cerps S; Menzel M; Hvidtfeldt M; Porsbjerg C; Uller L; Andersson CK
BMC Immunol; 2021 Jun; 22(1):35. PubMed ID: 34078278
[TBL] [Abstract][Full Text] [Related]
32. Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.
Fukuoka Y; Xia HZ; Sanchez-Muñoz LB; Dellinger AL; Escribano L; Schwartz LB
J Immunol; 2008 May; 180(9):6307-16. PubMed ID: 18424754
[TBL] [Abstract][Full Text] [Related]
33. Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds.
Huttunen M; Aalto ML; Harvima RJ; Horsmanheimo M; Harvima IT
Exp Dermatol; 2000 Aug; 9(4):258-65. PubMed ID: 10949547
[TBL] [Abstract][Full Text] [Related]
34. Increased numbers of tryptase-positive mast cells in the healthy and sun-protected skin of tobacco smokers.
Kaukinen A; Fitzgibbon A; Oikarinen A; Hinkkanen L; Viinikanoja M; Harvima IT
Dermatology; 2014; 229(4):353-8. PubMed ID: 25376107
[TBL] [Abstract][Full Text] [Related]
35. Human skin mast cells express complement factors C3 and C5.
Fukuoka Y; Hite MR; Dellinger AL; Schwartz LB
J Immunol; 2013 Aug; 191(4):1827-34. PubMed ID: 23833239
[TBL] [Abstract][Full Text] [Related]
36.
Li Z; Ji C; Cheng J; Åbrink M; Shen T; Kuang X; Shang Z; Wu J
Bioengineered; 2022 May; 13(5):13752-13766. PubMed ID: 35746853
[TBL] [Abstract][Full Text] [Related]
37. Sequential Increase in Complement Factor I, iC3b, and Cells Expressing CD11b or CD14 in Cutaneous Vasculitis.
Rahkola D; Lipitsä T; Siiskonen H; Naukkarinen A; Harvima IT
Anal Cell Pathol (Amst); 2022; 2022():3888734. PubMed ID: 35747245
[TBL] [Abstract][Full Text] [Related]
38. Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma.
Siiskonen H; Poukka M; Bykachev A; Tyynelä-Korhonen K; Sironen R; Pasonen-Seppänen S; Harvima IT
Melanoma Res; 2015 Dec; 25(6):479-85. PubMed ID: 26317168
[TBL] [Abstract][Full Text] [Related]
39. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase.
Schwartz LB; Kawahara MS; Hugli TE; Vik D; Fearon DT; Austen KF
J Immunol; 1983 Apr; 130(4):1891-5. PubMed ID: 6339618
[TBL] [Abstract][Full Text] [Related]
40. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
